Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274815 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 305
- Enrollment target
- 20
- Study locations
NCT05274815 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 305 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05274815, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 305 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller medications.
Conditions Studied
Interventions
- BIOLOGICAL Tezepelumab
Study Locations (20)
Other
- Research Site - Buenos Aires
- Research Site - CABA
- Research Site - CABA
- Research Site - Mendoza
- Research Site - Monte Grande
- Research Site - Pilar
- Research Site - Quilmes
- Research Site - Ranelagh
- Research Site - Rosario
- Research Site - San Fernando
- Research Site - San Juan Bautista
- Research Site - San Miguel de Tucumán
- Research Site - Brussels (Woluwé-St-Lambert)
California
- Research Site - Newport Beach
Delaware
- Research Site - Newark
Florida
- Research Site - Loxahatchee Groves
Michigan
- Research Site - Ann Arbor
New Jersey
- Research Site - Toms River
New York
- Research Site - The Bronx
Pennsylvania
- Research Site - DuBois
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2024-09-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05274815
The ClinicalTrials.gov registry entry for NCT05274815 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Tezepelumab is the first listed.
NCT05274815 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT05274815 about?
NCT05274815 is a clinical study titled "Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma". This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller medications.
What is the current status of trial NCT05274815?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 305 participants. The study started on 2022-05-17. Estimated completion is 2024-09-09.
What conditions does trial NCT05274815 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT05274815?
The interventions under investigation include: Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05274815?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05274815 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.